Johnson & JohnsonvsProgyny

JNJ and PGNY stock compared: price, dividend, valuation and results, from SEC filings.

PGNY

Progyny, Inc.

$36.05

Value $2.7B

-1.81%
PGNY's page

Johnson & Johnson (JNJ) has a market value of $664B and Progyny (PGNY) $2.7B. Over the last year, with dividends, JNJ moved +41.2% and PGNY +34.4%. The P/E is 41.3 for JNJ and 29.2 for PGNY. Dividend yield: JNJ 1.92%, PGNY none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$664B

    PGNY$2.7B

    JNJ is 250 times PGNY

  • Revenue, 12 months

    JNJ$99.3B

    PGNY$1.3B

    JNJ is 74 times PGNY

  • Net income, 12 months

    JNJ$16.1B

    PGNY$91M

    JNJ is 177 times PGNY

  • Operating margin

    JNJ–

    PGNY9.4%

  • ROIC

    JNJ12.4%

    PGNY18.2%

    5.8 points apart

  • P/E

    JNJ41.3

    PGNY29.2

    JNJ is 1.4 times PGNY

  • Dividend yield

    JNJ1.9%

    PGNY0.0%

    1.9 points apart

  • 5-year return

    JNJ+94.1%

    PGNY-42.3%

    136.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+94.1%

PGNY-42.3%

5010015020020222023202420252026
Returns by period
PeriodJNJWith dividendsPGNYWith dividends
1 year since November 17, 2025+41.2%Price +38.1%+34.4%Price +34.4%
3 years since November 17, 2023+100.4%+26.1% a yearPrice +84.0%+11.9%+3.8% a yearPrice +11.9%
5 years since November 17, 2021+94.1%+14.2% a yearPrice +68.8%-42.3%-10.4% a yearPrice -42.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonPGNYProgyny

Valuation

JNJPGNY
Valuation
Price$275.67$36.05
Market value$664B$2.7B
Enterprise value (EV)$692B$2.5B
P/E41.329.2
P/E, 5-year median21.949.7
P/B8.26.4
EV/EBIT39.019.6
Free cash flow yield3.1%6.8%

Results and growth

JNJPGNY
Results and growth
Revenue, 12 months$99.3B$1.3B
Net income, 12 months$16.1B$91M
Free cash flow, 12 months$20.6B$180M
Earnings per share, 12 months$6.59$1.09
Revenue growth, year on year6.1%10.4%
Revenue growth a year, past+2.7%over 5 years+30.2%over 5 years
EPS growth a year, past+14.9%over 5 years+6.7%over 5 years

Margins and returns on capital

JNJPGNY
Margins and returns on capital
Gross margin67.6%24.9%
Operating margin–9.4%
Net margin16.2%6.8%
ROIC12.4%18.2%
ROE19.7%19.1%

Balance sheet

JNJPGNY
Balance sheet
Cash$17.2B$196M
Total debt$44.7B$26M
Net debt / EBITDA1.1-1.5
Interest cover18.0×–

Dividends and buybacks

JNJPGNY
Dividends and buybacks
Dividend yield1.9%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%3.1%
Shareholder yield2.8%3.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or PGNY

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Progyny?

By market value, Johnson & Johnson ($664B) is about 250.3 times Progyny ($2.7B), at today's prices.

How did JNJ and PGNY stock do over the last 5 years?

Since November 17, 2021, JNJ's price moved +68.8% and PGNY's -42.3%. With dividends: JNJ +94.1% (+14.2% a year), PGNY -42.3% (-10.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or PGNY?

The dividend yield at today's price is 1.92% for Johnson & Johnson and none for Progyny. Over the last twelve months they paid $5.28 and – per share.

What is the P/E of JNJ and PGNY?

At today's price, the P/E is 41.3 for JNJ and 29.2 for PGNY. The median of the last five years was 21.9 and 49.7, which shows where each stands against its own past.

Which has the higher profit margins, Johnson & Johnson or Progyny?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 6.8% for Progyny, and the operating margin – and 9.4%. Revenue was $99.3B and $1.3B.

Which is the better investment, Johnson & Johnson or Progyny?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.